Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions.

TitleSelf-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions.
Publication TypeJournal Article
Year of Publication2010
AuthorsPark S, Kang S, Veach AJ, Vedvyas Y, Zarnegar R, Kim J-Y, Jin MM
JournalBiomaterials
Volume31
Issue30
Pagination7766-75
Date Published2010 Oct
ISSN1878-5905
KeywordsAnimals, Antineoplastic Agents, Biocompatible Materials, Drug Carriers, Drug Compounding, Drug Delivery Systems, HeLa Cells, Humans, Intercellular Adhesion Molecule-1, Lymphocyte Function-Associated Antigen-1, Materials Testing, Models, Molecular, Molecular Structure, Nanoparticles, Neoplasms, Pentacyclic Triterpenes, Polymers, Protein Conformation, Triterpenes
Abstract

Site-specific delivery of drugs while minimizing unwanted distribution has been one of the pursued goals in cancer therapy. In this endeavor, we have developed targeted polymeric nanoparticles called amphiphilic urethane acrylate nonionomer (UAN) for encapsulation of diverse water-insoluble drugs and diagnostic agents, as well as for simple and reproducible surface conjugation of targeting ligands. Using monoclonal antibodies or lymphocyte function-associated antigen-1 (LFA-1) I domain engineered for varying affinities to intercellular adhesion molecule (ICAM)-1, we were able to deliver UAN nanoparticles to human cancer cells with the efficiency dependent on the strength of the molecular interactions and the degree of ICAM-1 expression on cell surface. Compared to non-specific uptake of free drugs, targeted delivery of UAN nanoparticles carrying equal amount of drugs produced more potent cytotoxicity. Notably, without the targeting ligands attached, UAN nanoparticles were largely precluded from non-specific uptake by the cells, resulting in much lower toxicity. The versatility of our UAN nanoparticles in both payload encapsulation and presentation of targeting ligands may facilitate developing a robust platform for evaluating various combinations of cancer drugs and molecular interactions toward developing effective cancer therapy formulations.

DOI10.1016/j.biomaterials.2010.06.038
Alternate JournalBiomaterials
PubMed ID20667589
PubMed Central IDPMC2925180
Grant ListR01 GM090320 / GM / NIGMS NIH HHS / United States
Related Institute: 
Molecular Imaging Innovations Institute (MI3)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065